Open AccessHistological remission of eosinophilic esophagitis under asthma therapy with IL-5 receptor monoclonal antibody: A case report
Author(s) -
Marc Huguenot,
Anne-Catherine Bruhm,
Manfred Essig
Publication year - 2022
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v10.i14.4502
Subject(s) - benralizumab , medicine , eosinophilic esophagitis , mepolizumab , asthma , eosinophilic gastroenteritis , gastroenterology , eosinophilic , eosinophil , immunology , monoclonal , monoclonal antibody , disease , pathology , antibody
Benralizumab is a monoclonal antibody targeting the IL-5 receptor used in the treatment of asthma. The use of benralizumab in other conditions is only emerging and could represent a therapeutic option for other eosinophil-associated diseases. Here, we report the case of a patient suffering from eosinophilic esophagitis and asthma who achieved histological remission of eosinophilic esophagitis (EoE) under benralizumab treatment for his asthma.